Effect of Intrathecal magnessium sulphate on spinal anaesthesia at Korle-bu Teaching Hospital

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202406632360601

Enrollment

100

Registered

2024-06-21

Start date

2023-12-04

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anaesthesia

Interventions

None listed

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: ASA 2 pregnant women at term presenting for caesarean section. Ages 18 and above

Exclusion criteria

Exclusion criteria: Patient refusal Incisions other than Pfannenstiel Documented adverse reaction to 0.5% heavy bupivacaine or Magnesium sulphate Patients having coagulopathy, hepato-renal function derangements, uncontrolled hypertension, severe hypotension and arrhythmias. Body mass index > 35kg/m 2 Twin or complicated pregnancy Patients receiving anticoagulants for any cause Patients with spine deformities or neuropathy Patients unable to communicate making postoperative assessment difficult Failure of spinal block Patients with contraindications to spinal anaesthesia History of postoperative nausea and vomiting Patients on magnesium sulphate therapy

Design outcomes

Primary

Measure	Time frame
It is expected that the subjects in the groups with magnesium sulphate added intrathecally will have a prolong duration of analgesia following spinal block	—

Secondary

Measure	Time frame
It is expected that the subjects in the groups with magnesium sulphate added intrathecally will have less haemodynamic changes and side effects.	—

Countries

Ghana

Contacts

Public ContactRobert Djagbletey

Consultant

r_djag@yahoo.com+233244604456

Outcome results